# KarXT Concentrations in the Breast Milk and Plasma of Lactating Females

> **NCT07257120** · PHASE4 · RECRUITING · sponsor: **Karuna Therapeutics, Inc., a Bristol Myers Squibb company** · enrollment: 8 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Xanomeline/trospium chloride

## Key facts

- **NCT ID:** NCT07257120
- **Lead sponsor:** Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-09
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07257120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07257120, "KarXT Concentrations in the Breast Milk and Plasma of Lactating Females". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT07257120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*